<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01263080</url>
  </required_header>
  <id_info>
    <org_study_id>RECOVERY2</org_study_id>
    <nct_id>NCT01263080</nct_id>
  </id_info>
  <brief_title>Evaluation of Mirtazapine and Folic Acid for Schizophrenia:</brief_title>
  <acronym>RECOVERY2</acronym>
  <official_title>Multicentre Randomised Double-blind, Placebo-controlled 2x2 Factorial Trial Investigating the Effects of Adding Mirtazapine and Folic Acid to Existing Therapy for Patients With Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Capital Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Capital Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicentre randomised double-blind, placebo-controlled 2x2 factorial trial investigating the&#xD;
      effects of adding mirtazapine and folic acid to existing therapy for patients with&#xD;
      schizophrenia&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The combination of mirtazapine plus antipsychotic potentially offers considerable benefit for&#xD;
      patients with schizophrenia. Folic acid is a promising adjunctive therapy for schizophrenia&#xD;
      that may also provide benefits for patients with other mental disorders. Furthermore the&#xD;
      effects of folic acid may be affected by genotype.&#xD;
&#xD;
      The trial will investigate the effects of adding mirtazapine and the effects of adding folic&#xD;
      acid to treatments for schizophrenia. At randomisation, patients will be separately&#xD;
      randomised to mirtazapine or placebo and to folic acid or placebo.&#xD;
&#xD;
      Randomised, double-blind, placebo-controlled 2x2 factorial trial with 12-week follow-up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare the efficacy of mirtazapine and placebo for treatment of symptoms associated with schizophrenia</measure>
    <time_frame>baseline, week4, week8, week12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare the efficacy of folic acid and placebo for treatment of symptoms of schizophrenia</measure>
    <time_frame>baseline, week4, week8, week12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the efficacy of mirtazapine and placebo for treatment of negative symptoms of schizophrenia</measure>
    <time_frame>baseline, week4, week8, week12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the efficacy of folic acid and placebo for treatment of negative symptoms of schizophrenia</measure>
    <time_frame>baseline, week4, week8, week12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the safety and tolerability of mirtazapine and placebo in patients with schizophrenia</measure>
    <time_frame>baseline, week4, week8, week12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the safety and tolerability of folic acid and placebo in patients with schizophrenia</measure>
    <time_frame>baseline, week4, week8, week12</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">333</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>mirtazapine+folic acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>mirtazapine 30mg QD, folic acid 0.4mg QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mirtazapine+folic acid placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>mirtazapine 30mg QD, folic acid placebo 1 tablet QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mirtazapine placebo+folic acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>mirtazapine placebo 1 tablet QD, folic acid 0.4mg QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mirtazapine placebo+folic acid placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>mirtazapine placebo 1 tablet QD, folic acid placebo 1 tablet QD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mirtazapine</intervention_name>
    <description>mirtazapine 30mg QD</description>
    <arm_group_label>mirtazapine+folic acid</arm_group_label>
    <arm_group_label>mirtazapine+folic acid placebo</arm_group_label>
    <other_name>Remeron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>folic acid placebo</intervention_name>
    <description>folic acid placebo 1 tablet QD</description>
    <arm_group_label>mirtazapine placebo+folic acid placebo</arm_group_label>
    <arm_group_label>mirtazapine+folic acid placebo</arm_group_label>
    <other_name>Folic placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mirtazapine placebo</intervention_name>
    <description>mirtazapine placebo 1 tablet QD</description>
    <arm_group_label>mirtazapine placebo+folic acid</arm_group_label>
    <arm_group_label>mirtazapine placebo+folic acid placebo</arm_group_label>
    <other_name>Remeron placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>folic acid</intervention_name>
    <description>folic acid 0.4mg QD</description>
    <arm_group_label>mirtazapine placebo+folic acid</arm_group_label>
    <arm_group_label>mirtazapine+folic acid</arm_group_label>
    <other_name>vitamin B 9</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Inpatients or outpatients age 18 to 70 years;&#xD;
&#xD;
          2. Meet DSM-IV criteria for schizophrenia;&#xD;
&#xD;
          3. Signed an informed consent form by patients or their legally acceptable&#xD;
             representatives;&#xD;
&#xD;
          4. PANSS total score &gt;=60 and at least one item of P1, P2, P3, P5 or P6 &gt;=4 to ensure&#xD;
             subject has current active psychotic symptoms - i.e. hallucinations, delusions,&#xD;
             thought disorder;&#xD;
&#xD;
          5. Subjects who are currently taking effective dose of antipsychotic;&#xD;
&#xD;
          6. Women must agree to practice an effective method of birth control if they are sexually&#xD;
             active before entry and throughout the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Meet any other DSM-IV Axis I disorders;&#xD;
&#xD;
          2. Meet DSM-IV criteria for substance abuse or dependence;&#xD;
&#xD;
          3. Have been treatment-resistant to 2 or more kinds of antipsychotics with sufficient&#xD;
             dosage for at least 4 weeks, or require clozapine treatment, or have received&#xD;
             clozapine treatment within 1 month prior to randomization;&#xD;
&#xD;
          4. Subjects are actively suicidal or judged clinically to be at risk of serious suicidal&#xD;
             or violent behavior in the opinion of the investigator;&#xD;
&#xD;
          5. Have serious or unstable medical illness (e.g., cardiovascular disease, neurologic,&#xD;
             hematologic, renal, hepatic, immunologic, endocrine, or other systemic illness), or&#xD;
             have any clinically significant abnormality on laboratory test or ECG which indicate&#xD;
             severe medical conditions;&#xD;
&#xD;
          6. Have received electroconvulsive therapy within 28 days before randomization;&#xD;
&#xD;
          7. Have received long acting antipsychotic within 1 treatment cycle before randomization;&#xD;
&#xD;
          8. Have received antidepressant within 14 days, or have received MAOIs within 4 weeks&#xD;
             before randomization or require antidepressive treatment;&#xD;
&#xD;
          9. History of prostatic hypertrophy or dysuria;&#xD;
&#xD;
         10. History of narrow-angle glaucoma or elevation of intraocular pressure;&#xD;
&#xD;
         11. Known or suspected history of allergy or have contradiction to mirtazapine or folic&#xD;
             acid;&#xD;
&#xD;
         12. Known have currently requirement of taking mirtazapine or folic acid;&#xD;
&#xD;
         13. Women who are pregnant or nursing;&#xD;
&#xD;
         14. Have previously completed or withdrawn from this study, or participated in a clinical&#xD;
             trial of another drug within 30 days.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gang Wang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Anding Hospital, Capital Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing Anding Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100088</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>December 17, 2010</study_first_submitted>
  <study_first_submitted_qc>December 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2010</study_first_posted>
  <last_update_submitted>August 1, 2016</last_update_submitted>
  <last_update_submitted_qc>August 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Capital Medical University</investigator_affiliation>
    <investigator_full_name>Gang Wang</investigator_full_name>
    <investigator_title>vice-director of Affective Disorder Center, Beijing Anding Hospital</investigator_title>
  </responsible_party>
  <keyword>mirtazapine</keyword>
  <keyword>folic acid</keyword>
  <keyword>schizophrenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Vitamin B Complex</mesh_term>
    <mesh_term>Mirtazapine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

